STAT News
STAT+: Bayer sues J&J over ‘false and misleading claims’ about competing prostate cancer treatments
STAT News · Feb 23, 2026 · Collected from RSS
Summary
Bayer sued rival Johnson & Johnson for launching a “false advertising campaign” based on flawed data to wrongfully promote its drug as more effective.
Full Article
By Ed SilvermanFeb. 23, 2026 Pharmalot Columnist, Senior Writer Underscoring the high-stakes market for prostate cancer medicines, Bayer has filed a lawsuit accusing rival Johnson & Johnson of launching a “false advertising campaign” that uses flawed data to wrongfully promote its drug as a more effective treatment. At issue are claims J&J made in a Feb. 2 press release, as well as in presentations on its website, about its Erleada prostate cancer drug in comparison with a Bayer medication called Nubeqa. Both drugs are androgen receptor inhibitors that can prevent the growth of cancer cells and are frequently combined with other treatments. It was only last June that Bayer won U.S. regulatory approval to market its drug in combination with androgen deprivation therapy, posing new competition for the J&J drug. This prompted J&J to promote its medication as a superior choice in the press release and two website slide presentations aimed at physicians, the lawsuit stated. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
Share this story